Tag: underwriters

Boise, Idaho, July 06, 2026 (GLOBE NEWSWIRE) -- Idaho Copper Corporation (“Idaho Copper” and the “Company”) (NYSE American: COPR, COPR WS), a critical minerals developer advancing the flagship CuMo copper-molybdenum-silver project in Idaho, today announced the closing of its underwritten public offering of shares of its common stock and warrants at a public offering price of $4.85 per share and accompanying warrant for gross proceeds of approximately $18,000,000, before deducting underwriting discounts and offering expenses. In addition, Idaho Copper has granted the underwriters a 45-day option to purchase up to an additional 556,800 shares of common stock and/or warrants to cover over-allotments at the public offering price, if any. The offering also included the purchase by the underwriters of 556,800 warrants in connection with the partial exercise by the underwriters of their over-allotment option.

LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, which includes 741,758 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were approximately $259 million. All securities in the offering were sold by uniQure.

BEIJING, June 25, 2026 (GLOBE NEWSWIRE) -- DSC Holdings Ltd. (“DSC” or the “Company”) (NASDAQ: DSC), the AI application infrastructure for China’s used car industry, today announced that it has priced its initial public offering of 3,000,000 American depositary shares (“ADSs”) at US$17 per ADS, for a total offering size of approximately US$51 million, assuming the underwriters do not exercise their over-allotment option to purchase additional ADSs. Each ADS represents 20 Class A ordinary shares of the Company. The ADSs are expected to begin trading on the Nasdaq Global Market today under the ticker symbol “DSC.” The offering is expected to close on June 26, 2026, subject to customary closing conditions.

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the “Offering”).